For the Inventor, By the Inventor

Enter assignee name

Procell Therapeutics Inc.

USPTO Granted Patents = 10

EPO Patents = 5

Trademarks = 4

Forward Citations = 28

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Daewoong Jo (4 out of 4 patents)

Dae Woong Jo (3 out of 3 patents)

Thi Thuy Nga Do (3 out of 3 patents)

4. Minh Tam Duong (3 out of 3 patents)

5. Jin Sook Kim (3 out of 3 patents)

6. Kang Jin Lee (3 out of 3 patents)

7. Byung Kyu Lee (3 out of 3 patents)

8. Ki Deok Shin (2 out of 2 patents)

9. Sunny Lim (2 out of 2 patents)

10. Kyung Mi Park (2 out of 2 patents)

11. Jung Hee Lim (2 out of 2 patents)

12. Thi Lan Phuong Do (2 out of 2 patents)

13. Jung-Hee Lim (2 out of 2 patents)

14. Kisuk Park (2 out of 2 patents)

15. Jong Rae Kim (2 out of 2 patents)

10 patents: Sort by Forward Citations

1. 10300118 - Cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof (2019-05-28),

2. 9694087 - Development of novel macromolecule transduction domain with improved cell permeability and method for using same (2017-07-04),

3. 9259481 - Development of novel macromolecule transduction domain with improved cell permeability and method for using same (2016-02-16),

4. 9040477 - Macromolecule transduction domains and methods for identification and uses thereof (2015-05-26),

5. 8629097 - Macromolecule transduction domains and methods for identification and uses thereof (2014-01-14),

6. 8586544 - Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component (2013-11-19),

7. 8470971 - Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient (2013-06-25),

8. 8450279 - Cell permeable Nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same (2013-05-28),

9. 8445443 - Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same (2013-05-21),

10. 8158415 - Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells (2012-04-17),

Procell Therapeutics Inc. is a biotechnology company focused on developing novel cell-based therapies for a range of degenerative diseases. The company's proprietary technology platform enables the production of highly purified, pluripotent stem cells for use in regenerative medicine. Procell's pipeline includes therapies for conditions such as Parkinson's disease, spinal cord injury, and heart failure. With a strong commitment to scientific innovation and patient care, Procell Therapeutics is at the forefront of advancing cell-based therapies to improve human health.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

10 Patents

#42 in

#1,035 in South Korea

#54,349 in the World

Procell Therapeutics Inc.

Forward Citations = 28

24 inventors:

Daewoong Jo (4 out of 4 patents)

Dae Woong Jo (3 out of 3 patents)

Thi Thuy Nga Do (3 out of 3 patents)

4. Minh Tam Duong (3 out of 3 patents)

5. Jin Sook Kim (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…